AA
LUMO

ALPS Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

ALPS Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,049
Closed -$344K – 773
2015
Q4 		$344K Hold
1,049
– – ﹤0.01% 634
2015
Q3 		$3.38K Buy
+1,049
New +$461K ﹤0.01% 643

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ALPS Advisors's LUMO Position: Q1 2016 in Review

ALPS Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2016, closing a stake of 1,049 shares — an estimated $344K sold.

ALPS Advisors first reported a position in LUMO in Q3 2015 and held it in 2 quarters. The position peaked at $344K in Q4 2015. 139 funds tracked by Wall St. Rank hold LUMO as of Q1 2016.

  • ALPS Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • ALPS Advisors sold 1,049 Lumos Pharma, Inc. Common Stock shares in Q1 2016, an estimated $344K.
  • ALPS Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2015 and held it in 2 quarters.
  • ALPS Advisors's Lumos Pharma, Inc. Common Stock position peaked at $344K in Q4 2015.
  • 139 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2016.

Based on ALPS Advisors's 13F filing for Q1 2016, filed 10 May 2016.